Valeant Pharmaceuticals Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Valeant Pharmaceuticals (VRX) PT to $285 at BMO Capital Following 'Strong and Clean' Quarter
July 24, 2015 7:45 AM EDTBMO Capital analyst Alex Arfaei reiterated an Outperform rating and boosted his price target on Valeant Pharmaceuticals (NYSE: VRX) to $285.00 (from $266.00) following a 'strong and clean quarter.'
Arfaei commented, "quarter. The legacy Valeant business in the US continues to exceed our expectations, driven by the US dermatology and Bausch + Lomb (B+L) businesses, including new product... More
Valeant Pharma (VRX) Misses Q2 EPS by 10c; Boosts FY15 Outlook
July 23, 2015 6:02 AM EDTValeant Pharma (NYSE: VRX) reported Q2 EPS of $2.46, $0.10 worse than the analyst estimate of $2.56. Revenue for the quarter came in at $2.73 million, versus $2.04 million reported last year.
Valeant Pharma sees Q3 2015 EPS of $2.60-$2.70. Valeant Pharma sees Q3 2015 revenue of $2.6-2.8... More
